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Purpose: To investigate the clinical characteristics and therapeutic outcome of patients with 
neovascular age-related macular degeneration (nAMD) in 1 eye, without drusen in the fellow eye.
Patients and methods: Medical records of 381 patients were analyzed to identify the cases. 
The main outcomes included Early Treatment Diabetic Retinopathy Study (ETDRS) best-
corrected visual acuity (BCVA) and change in central retinal thickness (CRT). These parameters 
were reviewed at baseline, first follow-up visit, and after 6, 12, and 24 months.
Results: Out of 381 patients, 29 cases (8%) were included (of whom 3 had polypoidal choroidal 
vasculopathy [PCV]) who were treated with anti-vascular endothelial growth factor (anti-VEGF) 
therapy which was supplemented by photodynamic therapy (PDT) in the PCV patients. Over-
all, no statistically significant change in mean BCVA was observed during follow-up. BCVA 
improved or remained stable (defined as a gain in BCVA, a stable BCVA, or a loss of ,5 ETDRS 
letters) in 22 patients (76%), and 7 patients (23%) had lost $5 ETDRS letters at final follow-up. 
A gain of $15 ETDRS letters at final follow-up was seen in 5 patients (17%). Mean CRT had 
decreased significantly with 99 µm (P,0.001) at 24 months after the initial visit.
Conclusion: There is a clinical spectrum of nAMD that is not associated with drusen in the fel-
low eye. Patients with nAMD without drusen in the fellow eye respond to anti-VEGF treatment 
and, in cases of PCV, to supplemental PDT. The pathophysiology of this spectrum of nAMD 
may be different from drusen-associated age-related macular degeneration.
Keywords: anti-vascular endothelial growth factor, unilateral age-related macular degenera-
tion, non-neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, 
precursor lesion, best-corrected visual acuity
Introduction
Age-related macular degeneration (AMD) is the most common cause of irreversible 
vision loss among elderly in the Western world. Marked vision loss can occur in late 
AMD, as a result of choroidal neovascularization (CNV) and/or profound chorioretinal 
atrophy (geographic atrophy).1
Traditionally, macular drusen are characteristic for early and intermediate stages of 
this disease. However, the definition of AMD has varied among authors.2–4 Although 
most classifications consider drusen mandatory lesions in AMD, 1 or more small hard 
drusen with a diameter ,63 µm can be detected in 85%–99% of the overall popula-
tion aged $50 years.5–8 
In cases of unilateral neovascular AMD (nAMD), the fellow eye is at high risk 
of developing CNV, with cumulative incidence rates of 10%, 22%, 28%, 37%, and 
42% after 1, 2, 3, 4, and 5 years, respectively.9,10 Factors that contribute to these rates 
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are the presence, number, location, and the individual and 
cumulative size of drusen in the fellow eye.11 However, there 
is a clinical observation that some patients with nAMD in 
1 eye with no drusen in the fellow eye. Little is known about 
the clinical characteristics and therapeutic outcome of this 
subgroup of patients with unilateral nAMD without drusen in 
the fellow eye. As drusen are often considered pivotal precur-
sor lesions for advanced AMD such as nAMD, the question 
arises whether nAMD without drusen in the fellow eye is 
clinically distinct from drusen-associated nAMD. Therefore, 
this study analyzed the clinical spectrum, characteristics, and 
treatment outcome of a subgroup of patients with nAMD in 
1 eye, without drusen in the fellow eye.
Patients and methods
Data collection
A retrospective review of charts was performed at the Depart-
ment of Ophthalmology of Leiden University Medical Center, 
the Netherlands. This study adhered to the tenets of the Declara-
tion of Helsinki, and approval for this study was obtained from 
the Medical Ethical Committee of Leiden University Medical 
Center. All participants gave their written informed consent.
All data were obtained from patients who were diagnosed 
with unilateral nAMD between January 2010 and July 2015. 
These cases were retrospectively analyzed to identify cases 
of unilateral nAMD without drusen in the macular region of 
the fellow eye at initial diagnosis. The grading of drusen was 
performed according to the International Classification for age-
related maculopathy and AMD,2 and the location of the lesions 
was determined using the Early Treatment Diabetic Retinopathy 
Study (ETDRS) grid. Fellow eyes with ,5 small hard drusen 
with a diameter ,63 µm in the macular region were not consid-
ered to have AMD, but rather a consequence of normal aging.3 
All images were obtained from routine eye examinations and 
were assessed by an experienced retina specialist (CJFB). 
Patients had to meet all of the following inclusion criteria: 
1) age $50 years; 2) AMD with signs of CNV confirmed 
on optical coherence tomography (OCT) (on which either 
subretinal or intraretinal fluid or both could be detected) and 
fluorescein angiography (FA) in 1 eye; 3) ,5 small hard 
drusen in the macular region in the fellow eye as evidenced by 
fundus photography, FA, and OCT; 4) at least 1 follow-up 
visit after initial diagnosis. Exclusion criteria were any of 
the following: 1) multimodal imaging which was consid-
ered to be of insufficient quality; 2) a confirmed diagnosis 
of AMD with signs of CNV or fovea-involving atrophy 
in the fellow eye; 3) history of another diagnosis as a pri-
mary underlying cause/background of neovascularization, 
such as pseudoxanthoma elasticum, high myopia (ie, $6 
diopters), central serous chorioretinopathy (CSC), macular 
telangiectasia, or multifocal choroiditis. 
image acquisition
All patients included in this study underwent color fundus 
photography (Topcon Corp., Tokyo, Japan), OCT with either 
the Cirrus OCT (Carl Zeiss Meditec, Dublin, CA, USA) 
or spectral-domain OCT device (Spectralis HRA + OCT; 
Heidelberg Engineering, Heidelberg, Germany), and FA 
was performed with either a Topcon fundus camera (Topcon 
Corp.) or the Spectralis HRA + OCT camera.
study measurements
After patient selection, the following clinical parameters 
were collected at baseline: age at onset, best-corrected visual 
acuity (BCVA), the anatomical level of fluid accumulation 
on OCT (intraretinal, subretinal, or both), performed treat-
ments (anti-vascular endothelial growth factor [anti-VEGF] 
treatment [bevacizumab, ranibizumab, and aflibercept] and/or 
photodynamic therapy [PDT]), central retinal thickness 
(CRT), and the type of CNV. The type of CNV was either 
“type 1” (sub-retinal pigment epithelium [RPE] neovascu-
larization [occult neovascularization]), “type 2” (subretinal 
neovascularization [classic neovascularization]), or “type 3” 
(retinal angiomatous proliferation).12,13 In case of a mixed 
neovascularization, the CNV was considered to be “mini-
mally classic” if the majority of the CNV was type 1. If the 
mixed neovascularization was predominantly type 2, it was 
referred to as “predominantly classic,”13 The first choice 
of anti-VEGF treatment in treatment-naive patients was 
3 monthly intravitreal injections of bevacizumab. Switching 
to another type of anti-VEGF treatment (either ranibizumab 
or aflibercept) was considered when insufficient reduction 
in subretinal and/or intraretinal fluid was observed on OCT 
at a control examination within 4 weeks after the third 
bevacizumab injection. Indocyanine green angiography was 
performed either in case of a suspicion of polypoidal chor-
oidal vasculopathy (PCV) or when patients did not respond 
sufficiently to anti-VEGF treatment. Treatments were applied 
according to the pro re nata regimen, where patients had a 
follow-up every 4 weeks after initial treatment. Retreatment 
of 3 injections every 4 weeks was performed upon reoccur-
rence of subretinal and/or intraretinal fluid on OCT and/or on 
FA, or when hemorrhage was seen during fundoscopy.14 
Information regarding BCVA and CRT was collected 
at the first visit before initial treatment (baseline), at the first 
visit after initial treatment, which was usually scheduled after 3 
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intravitreal injections, and 6, 12, and 24 months after initial 
treatment. For patients for whom ETDRS BCVA was not 
available, a previously published formula was used to convert 
Snellen BCVA to ETDRS values.15 The number and mode 
of anti-VEGF injections during follow-up, and changes in 
subretinal and/or intraretinal fluid on OCT were recorded. 
The used dosages of bevacizumab, ranibizumab, and 
aflibercept were 1.25, 0.5, and 2 mg, respectively. In order 
to quantify the number of anti-VEGF injections required to 
achieve a total resolution of subretinal and/or intraretinal fluid 
for $3 months without treatment, OCT images were used. 
statistical analysis
Statistical analysis was performed using IBM SPSS Statistics, 
version 23 (IBM Corporation, Armonk, NY, USA). The 
clinical parameters at baseline and during follow-up were 
analyzed in an autoregressive model within a linear mixed 
model with time as a factor. A P-value of ,0.05 was con-
sidered to be statistically significant. 
Results
Fundus photography, FA, and OCT of 381 patients were 
analyzed to identify cases within the spectrum of unilateral 
nAMD without drusen in the macular region of the fellow 
eye at initial diagnosis. Twenty-nine patients (8%) (16 male 
and 13 female patients) met the inclusion criteria. The mean 
age at onset of disease of these 29 patients was 75 years 
(range: 53–89 years). In 1 patient (3%), a few small hard 
drusen were found in the eye with nAMD (Table 1). A spec-
trum of neovascular abnormalities was observed (Figure 1): 
18 patients were diagnosed with type 1 neovascularization, 
7 patients with type 2 neovascularization, and 4 patients with 
a mixed neovascularization. Three of these 29 patients (10%) 
were also diagnosed with PCV (of whom in 1 patient the 
lesion was an isolated polyp, and in 2 patients the lesions 
occurred together with a neovascularization/branching vas-
cular network, confirmed on additional indocyanine green 
angiography) (Table 1). Patients received the first intravitreal 
injection at a mean of 7 days (range: 0–16 days) after being 
diagnosed with nAMD. Some patients were also scheduled 
for either half-dose or full-dose PDT (Table 2). In none of 
the patients, ophthalmic surgery had been performed in their 
study eye during follow-up. One patient received cataract 
surgery in the fellow eye during the study.
Overall, BCVA in all patients increased with a mean of 
2.5 ETDRS letters at 24 months, which was not statistically 
significant as compared to baseline (P=0.456) (Figure 2). 
The BCVA of 22 patients (76%) improved or remained 
stable (defined as a gain in BCVA, a stable BCVA, or a loss 
of ,5 ETDRS letters), whereas BCVA decreased (defined 
as a loss of $5 ETDRS letters) in 7 patients (24%). A gain 
of $15 ETDRS letters from baseline was seen in 5 patients 
(17%). The BCVA of the 3 PCV patients during follow-up 
and the treatments performed in these patients are shown 
separately (Table 3). 
Compared to baseline, the mean CRT had significantly 
decreased with 99 µm (P,0.001) at final follow-up 
(Figure 3). At all follow-up visits, the decrease in CRT 
was statistically significant (Figure 3). Based on the type 
of neovascularization, no significant difference in CRT 
decrease between the 2 groups at several time points was 
found (Figure 4).
In 6 of 29 treated patients (21%), there were no signs of 
CNV activity on OCT for $3 months (Table 4) after baseline. 
However, 1 patient needed full-dose PDT after 8 intravitreal 
bevacizumab injections and 3 ranibizumab injections before 
a complete resolution of subretinal and/or intraretinal fluid 
was achieved for these 3 months.
Table 1 Baseline characteristics of patients with neovascular 
age-related macular degeneration without drusen in the fellow eye
Baseline characteristics
n 29
gender, (n [%])
Male 16 (55)
Female 13 (45)
age at onset (mean ± sD) 75±10 years
Diagnosis
naMD (n) 26
PCV (n) 3
number of patients with drusen in the eye with naMD 1/29
Type of CnV
Type 1 (n) 18
Type 2 (n) 7
Mixed, minimally classic (n) 2
Mixed, predominantly classic (n) 2
eTDrs BCVa letter score (mean ± sD) 57±24
snellen equivalent (mean ± sD) 20/67±20/333
Central retinal thickness (µm) (mean ± sD) 408±154
number of patients who completed follow-up
6 months 25/29
12 months 23/29
24 months 17/29
number of days until follow-up visit (mean, range)
First follow-up 86 (14–154)
6 months 192 (153–280)
12 months 356 (302–431)
24 months 703 (520–995)
Abbreviations: BCVa, best-corrected visual acuity; CnV, choroidal neovas-
cularization; eTDrs, early Treatment Diabetic retinopathy study; naMD, 
neovascular age-related macular degeneration; PCV, polypoidal choroidal 
vasculopathy; sD, standard deviation.
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Figure 1 spectrum of neovascular age-related macular degeneration without drusen in the fellow eye.
Notes: (A–D) Multimodal imaging of a 72-year-old female patient with neovascular age-related macular degeneration. Fundus photography (A) showed a central macular 
neovascular lesion with hemorrhage. On Fa (B), a type 2 neovascularization was present. On OCT (C), accumulation of hyperreflective subretinal debris and subretinal fluid 
was visible. On OCT of the fellow eye (D) at initial diagnosis, no drusen were present. (E–I) Multimodal imaging of a 64-year-old female patient with polypoidal choroidal 
vasculopathy. On fundus autofluorescence (E), serous maculopathy and a PeD in the macular region were visible. Fa (F) showed a type 2 neovascularization. The indocyanine 
green angiograph (G) revealed a polyp below the PeD. On OCT (H), hyperreflective material below the retinal pigment epithelium was seen. On OCT of the fellow eye (I) 
no drusen were present.
Abbreviations: FA, fluorescein angiography; OCT, optical coherence topography; PED, pigment epithelial detachment.
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Discussion
This study examined the clinical spectrum and therapeutic 
outcome of patients with unilateral nAMD without drusen 
in the macular region of their fellow eye. In these patients, 
no statistically significant improvement in BCVA occurred 
after a follow-up of 24 months after first treatment for nAMD. 
Moreover, in 7 patients (24%), the BCVA declined with $5 
ETDRS letters. Overall, the mean decrease in CRT was sta-
tistically significant at the final follow-up visit. In all patients, 
the mean increase in BCVA in this study was 2.5 ETDRS 
letters at the last follow-up visit at 24 months after baseline, 
which is relatively low in comparison with other studies. In 
these studies, a statistically significant increase in BCVA of 
14 and 6–7.9 ETDRS letters was found from baseline until 
the follow-up visits at 12 and 24 months, respectively, after 
using intravitreal injections according to the pro re nata 
regimen.16,17 However, the mean number of intravitreal injec-
tions used in our study over the period of 24 months, and 
the significant decrease in CRT at 24 months after baseline, 
is comparable to another study.17 This may suggest that 
subgroups of AMD could have a different prognosis and 
that different treatment strategies may be needed to achieve 
a significant improvement in BCVA.
The correlation between nAMD and clinical charac-
teristics of non-neovascular fellow eyes has been studied 
previously.18–20 Available studies indicate a correlation 
between the subtype of neovascularization, based on the 
anatomical classification, and phenotypic characteristics of 
the non-neovascular fellow eyes.18,19 Predominantly, intrareti-
nal lesions are more likely to be accompanied by reticular 
pseudodrusen and/or a decreased subfoveal choroidal thick-
ness compared to supra-RPE lesions.19 Other studies have 
shown an association between the development of nAMD 
and reticular pseudodrusen in the fellow eye.18 However, no 
studies of patients with unilateral nAMD without any drusen 
in the fellow eye have been performed thus far. 
Patients with nAMD without drusen in the fellow eye 
could be argued to have overlapping phenotypes and/or 
phenocopies mimicking AMD, which share clinical and pos-
sibly pathophysiologic features with drusenoid AMD, such 
as idiopathic PCV, and neovascular CSC.21,22 At baseline 
only 1 patient (3%) had a few small hard drusen in the eye 
with nAMD. The remaining patients (97%) had no drusen in 
Table 2 Treatment and number of received intravitreal injections during follow-up
Treatment after baseline visit until first follow-up visit
Bevacizumab (number of patients/mean number of injections) 21/2.95
ranibizumab (number of patients/mean number of injections) 2/2
PDT* + bevacizumab (number of patients/mean number of injections) 4/3.50
Treatment from first follow-up visit until 6 months after initial diagnosis
Bevacizumab (number of patients/mean number of injections) 15/2.53
ranibizumab (number of patients/mean number of injections) 3/3.33
PDT** + aflibercept (number of patients/mean number of injections) 1/2
Treatment from 6 months until 12 months after initial diagnosis
Bevacizumab (number of patients/mean number of injections) 11/3.09
ranibizumab (number of patients/mean number of injections) 4/4.75
Aflibercept (number of patients/mean number of injections) 4/3.50
PDT*** + aflibercept (number of patients/mean number of injections) 1/3
Treatment from 12 months until 24 months after initial diagnosis
Bevacizumab (number of patients/mean number of injections) 10/4.60
ranibizumab (number of patients/mean number of injections) 2/4.50
Aflibercept (number of patients/mean number of injections) 4/3.50
Notes: *During this time frame 3 patients received 1 session full-dose PDT and 1 patient received 1 session of half-dose PDT. **1 session of half-dose PDT. ***1 session 
of full-dose PDT.
Abbreviation: PDT, photodynamic therapy.
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Figure 2 Mean change in BCVa during follow-up, compared to baseline.
Note: *Indicates statistical significance.
Abbreviations: BCVa, best-corrected visual acuity; eTDrs, early Treatment 
Diabetic retinopathy study; se, standard error.
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Figure 3 Mean change in CrT during follow-up, compared to baseline.
Note: *Indicates statistical significance.
Abbreviations: CrT, central retinal thickness; se, standard error.
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Figure 4 Mean CrT during follow-up per type of neovascularization (type 1 versus 
type 2).
Notes: Δ indicates the difference in decrease of CrT between the 2 subgroups 
(decrease in µm within the patient group with type 1 neovascularization minus the 
decrease in µm within the patient group with type 2 neovascularization).
Abbreviations: CrT, central retinal thickness; se, standard error.
their eye with nAMD. A possible explanation for this find-
ing is that drusen in earlier stages may regress before being 
converted to advanced nAMD.23 The clinical observation 
that some patients can have this type of unilateral nAMD 
raises the question whether these patients truly have AMD in 
the strict sense, because early AMD is characterized by the 
appearance of drusen with a size of .63 µm in either eye.3,6 
However, this study excluded patients with other diagnoses 
explaining the occurrence of CNV, such as pseudoxanthoma 
elasticum, high myopia, CSC, macular telangiectasia, or 
multifocal choroiditis. The mean age at onset of the nAMD 
patients in this study was 75 years, and CNV in the affected 
eye could be easily classified as type 1 or 2 (or mixed type) 
CNV, sometimes with a component of PCV. Apart from an 
absence of drusen in the fellow eye in the current patient 
group, any drusen in the eye affected by nAMD was also 
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age-related macular degeneration without drusen in the fellow eye
not observed although the absence of drusen in the case of 
neovascularization is not a definitive proof that these were 
not present prior to the onset of nAMD. It is therefore argued 
that the patient group that is described here truly has a form 
of nAMD although they do not have drusen in the fellow 
eye. This study seems to point out that for a subgroup of 
nAMD patients the presence of drusen is not a prerequisite 
to develop nAMD, as evidenced indirectly by an absence of 
drusen in the fellow eye.
Drusen are located between the RPE and Bruch’s mem-
brane and consist of a broad spectrum of components, such as 
proteins that are involved in the complement system.24 Drusen 
are considered to be by-products of chronic, local inflamma-
tory events in Bruch’s membrane and play an important role 
in the pathogenesis and progression of AMD.24 They also 
contain esterified and unesterified cholesterol which may be 
produced by the RPE.25,26 Moreover, strong evidence has been 
found that genes involved in lipid transport and processing 
are consistent with the composition of drusen.27 It is possible 
that the current patient cohort had earlier, clinically invisible 
underlying pathophysiologic signs such as basal laminar 
deposits and basal linear deposits, and membranous debris 
in the fellow eye without visible drusen, which may then 
still cause a drusenoid environment with pathophysiological 
consequences such as CNV.28 A better understanding of the 
development of drusen in nAMD, and the possible prerequi-
site of drusen or their precursor material to cause CNV, could 
provide insight in the pathogenesis, prognostic factors, and 
intervention strategies for CNV in all nAMD patients. 
Although the number of Caucasian PCV patients (10%) 
involved in this study is too small to draw conclusions 
about the therapeutic outcome in this specific subgroup, 
these patients appeared to respond to a treatment combi-
nation of PDT and intravitreal anti-VEGF injections. The 
prevalence of PCV in Caucasians seems to be substantially 
lower than in Asians,29 and Caucasian PCV patients may 
differ from PCV patients with an Asian ethnicity in terms of 
presenting clinical features and angiographic behavior.29–31 
Larger studies are necessary to explore the differences in 
phenotypes, genotypes, and treatment response between 
the Caucasian and Asian population. It is currently unclear 
whether PCV can be seen as a specific pathogenetic and/or 
clinical entity within the spectrum of AMD in Caucasians, or 
as a variant of CNV.32,33 There is evidence that PCV shares 
characteristics with nAMD, but different phenotypic subtypes 
are also possible.34 
The findings of this study clearly indicate that there is 
an entity of unilateral AMD without drusen in the fellow 
eye. This is the first exploratory study assessing the clinical 
characteristics and therapeutic outcome of patients with 
nAMD and no drusen in the fellow eye. The retrospec-
tive aspect and non-comparative nature of this study gives 
its inherent shortcomings. In some cases, different OCT 
machines were used during follow-up for CRT measure-
ments. Only 17 of the 29 (59%) included patients in the cohort 
had a follow-up of 24 months. Larger, preferably prospective 
clinical studies can provide a better understanding of this spe-
cific subgroup of AMD. It was demonstrated that therapeutic 
response in patients with unilateral nAMD without drusen 
in the fellow eye could differ from typical nAMD patients. 
These findings indicate that drusen as precursor lesions may 
not be a prerequisite to develop nAMD.
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